Abstract
Objective: The patient with a diagnosis of heparin-induced thrombocytopenia and thrombosis who requires urgent cardiac surgery represents a formidable challenge. Among the alternatives to heparin, argatroban has gained widespread use in non-cardiac surgery patients. The object of this communication is to report our recent experience with this agent during cardiopulmonary bypass (CPB) and to review the cases previously published in order to better define indications, dosage, monitoring and limitations in cardiac surgery patients. Methods: A case of mitral valve replacement where argatroban was used for anticoagulation during CPB is described. The literature on the subject is reviewed and the relationship between argatroban dosage and activated clotting time (ACT) is studied by regression analysis. Results: Clotting of the oxygenator requiring prompt replacement occurred after release of cross-clamp. Upon termination of the drug, ACT remained elevated beyond the expected half-life. A significative (P
Original language | English |
---|---|
Pages (from-to) | 592-596 |
Number of pages | 5 |
Journal | Interactive Cardiovascular and Thoracic Surgery |
Volume | 10 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2010 |
Keywords
- Blood coagulation/anticoagulation
- Cardiopulmonary bypass
- Physiology/pathophysiology
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pulmonary and Respiratory Medicine
- Surgery